In this preliminary study of few patients, we have observed a potential usefulness of Supportan(®) in the compliance of concurrent RT-CHT in patients with H&N cancers; moreover, its administration was useful to maintain the initial biochemical nutritional profile.

Nutritional status depression in persons suffering from head and neck cancer has been scarcely study. An inadequate nutrient intake could be the principal factor (1)(2)(3) . Previous study in a group of patients underwent conventional therapy showed changes in specific serum protein fractions, indicative of an impairment of nutritional status and inflammation (4) . The goal is the evaluation of nutritional status through the use of biochemical parameters in a subgroup of adult patients suffering from head and neck cancer before and after oral intake of a nutritional supplement.The study was performed on seven patients (n = 7, 45-60 years old), who were attended in the Angel Roffo Institute, with local advanced head and neck cancer, underwent therapy with Chemoradiotherapy that completed oral intake of a nutritional supplement, during 60 days (Supportan 1 , Fresenius-Kabi ). The supplement provides 500 Kcal/day, with 27 % of total calories cover by proteins, 40 % by lipids (2 g EPA provided by fish oil, MCT and vegetal oils) and 33 % of carbohydrates. Patients had not severe mucositis -ulcera, bleeding and/or infection. Never of them had another severe toxicity by treatment nor had impairment of Perfomance Status. Blood samples were collected from fasting patients before (To) and after (Tf) the oral administration of the supplement. Specific serum protein fractions of potential usefulness in nutrition studies: transthyretin (TTR), transferrin (Transf), C3 (C3c), and C4 (C4c); acute phase serum fractions: ceruloplasmin (Cp), haptoglobin (Hp) and protein C reactive (PCR) were measured by single radial immunodiffusion technique on agar gel layers (Biocientífica S.A., Argentina and Binding Site, UK). Biochemical parameters (Tf vs To) (mg/dl),expressed as X (SD) were: TTR: 21.1 (8.9) vs 22.9 (7.3); Transf: 188.9 (36.1) vs 207.3 (20.9); C3c:122.6 (24.9) vs 122.5 (52.3); C4c: 37.5 (7.4) vs 38.9 (11.1); Cp: 40.0 (6.7) vs 36.1(11.7), Hp: 334.0 (194.2) vs 245.6 (103.9); PCR: 1.4 (0.3) vs 1.6 (2.1). No differences between Tf and To were observed. These preliminary results suggest that the oral supplement administration was useful to maintain the initial biochemical nutritional profile. As a matter of fact, we consider a probable beneficial tendency in the implementation of this oral supplement to this type of treatment for head and neck carcinoma.

participate. Overall, 251 pts were identified. At each center, up to 6 pts who started olaparib (400 mg bid, capsule formulation) between 03/2014 and 03/2017 were randomly selected and included. Medical records were reviewed for clinic and pathologic characteristics, survival outcomes and safety. Our primary objective was to assess efficacy of olaparib in real-world pts treated upon initial EMA label (pts EMA ) by evaluating progression free survival (PFS) from olaparib initiation.Results: Overall, 128 pts were included in the analysis and 89 were treated according to EMA label. Main reasons to be given olaparib off-label were absence of radiological response following platinum-based chemotherapy (n¼22) and non high-grade serous EOC subtype (n¼14). BRCA1/2 mutation was present in 126 pts (98%). Most pts (68%) received olaparib after 3 or more lines of platinum-based chemotherapy. Median follow up was 41.8 months. Median PFS in pts EMA was 17.0 months (95% CI: 14.7-21.3). Median PFS and overall survival (OS) in the whole population were 15.5 months (95% CI: 12.6-18.1) and 33.6 months (95% CI: 28.7; 40.3), respectively. Fourteen (11.2%) pts stopped olaparib for toxicity reason and 75 (58.6%) had at least one dose reduction or one dose interruption. Related myelodysplastic syndrome and second cancers were diagnosed in respectively n¼5 and n¼1 pts. Number of previous lines of systemic therapy 2 was associated with prolonged PFS.Conclusions: With an extended follow-up, efficacy and toxicity of olaparib in realworld cohort of pts are consistent with findings observed in study 19 and SOLO-2 trials.Clinical trial identification: NCT04152941.Legal entity responsible for the study: ARCAGY-GINECO.

Background: Gastric cancer represents the fifth most common tumor and the thirdleading cause of cancer-related death worldwide. The results of surgical treatment of locally advanced gastric cancer remain generally poor due to the high rate of relapse after surgery. In the last decade, neoadjuvant chemotherapy has become the standard of care for patients with stage IB resectable advanced gastric cancer. The benefit in progression-free and overall survival was confirmed by several randomised trials and meta-analyses compared to immediate surgery. However, data in the "reallife" setting are rare. We conducted a retrospective study to clarify the question of whether this benefit is achievable under real-life conditions.Methods: Our retrospective study concerned patients with histologically-confirmed advanced gastric cancer clinical stage II-IIIc according to UICC (8th edition) treated at the University Hospital of Marrakech between January 2017 and December 2018. They received 2-4 cycles/3 weeks of neoadjuvant chemotherapy based on FLOT, FOLFOX, XELOX, EOX or 5FU-Cisplatin protocols.Results: 48 patients with a median age of 56 years were diagnosed with advanced gastric cancer. 67% of them are male were. Only 16 patients (33,3%) had received neoadjuvant chemotherapy and 19 were operated immediately (39,5%). Protocols used in perioperative were FLOT in 8 patients (50%) and FOLFOX in 4 patients (25%). The rest have received either EOX (1 patient), XELOX (2 patients) or 5FU-cisplatin (1 patient). 7 patients (43,75%) received 4 cycles of neoadjuvant chemotherapy. Side effects were represented by mycosis grade 2 in 2 patients, neutropenia grade 2 in 4 patients and only one patient had grade 3 toxicity. After neoadjuvant chemotherapy, we observed 3 cases of partial response and 4 of stable disease. 5 patients (31,25%) underwent surgery (R0 in all cases) by total gastrectomy and D2 lymphadenectomy. 68,42% of the group who did not receive neoadjuvant chemotherapy, were treated by concomitant chemoradiotherapy. The median overall survival in the neoadjuvant group was 21 months compared to only 12 in the second group. Conclusion:Despite the small number of patients treated, our analysis showed that selected patients with locally advanced adenocarcinoma can be safely managed with perioperative chemotherapy in daily clinical practice and our results confirm the survival benefit of perioperative treatment. abstracts Annals of Oncology Volume 31 -Issue S3 -2020 S191

No abstract